Coronavirus (COVID 19) Vaccine  Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis Report by 2026

Overview of “Coronavirus (COVID 19) Vaccine Market” Report Helps In Providing Scope and Definitions, Key Findings, Growth Drivers, and Various Dynamics.

“Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020” provides a comprehensive analysis of the fast-evolving, high-growth global Coronavirus (COVID 19) vaccine market. The report offers the most up-to-date industry data on the actual market situation for the Coronavirus (COVID 19) vaccine.

The report explores a detailed analysis of the introduction of the coronavirus, pathogen characteristics, signs and symptoms, transmission, and prevention. It also evaluates the vaccines developed against MERS-CoV and SARS-CoV. The report reviews a clear insight into the funding of the Coronavirus (COVID-19) vaccine research. The report also offers comprehensive information about the recruiting clinical trials statement by phase, trial status, study sponsor name, and study phase. The report investigates detailed insights about countries, territories, or areas with reported laboratory-confirmed Coronavirus (COVID-19) cases and deaths. Key trends in terms of collaboration and partnership deals are analyzed with details.

Download PDF Sample of Coronavirus (COVID 19) Vaccine Market report @ https://www.arcognizance.com/enquiry-sample/960035 

The report concludes with the profiles of the key vaccine developers in the global coronavirus vaccine market. The key players are evaluated on the various parameters such as business overview, promising vaccine in clinical development, and recent development.

Report Scope:

• Extensive coverage of the Coronavirus (COVID-19) vaccine under development
Detailed Insights of the Introduction, Pathogen Characteristics, Signs and Symptoms, Transmission and Prevention
Provides Comprehensive Insights on the Funding of the Coronavirus (COVID-19) Vaccine Research
Thoroughly Evaluates Vaccines Developed Against MERS-CoV and SARS-CoV
Reviews Most Recent Clinical Trials of the Coronavirus Vaccines
Scrutinizes Countries, Territories or Areas with Reported Laboratory-Confirmed Coronavirus (COVID-19) Cases and Deaths
Provides Key Trends with Respect to Collaboration and Partnership Deals
An Insightful Analysis of the Key Vaccine Developers Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

Brief about Coronavirus (COVID 19) Vaccine Market Report with TOC@ https://www.arcognizance.com/report/coronavirus-covid-19-vaccine-pipeline-assessment-2020

Key Vaccine Developers Covered in the Report

• University of Oxford
Clover Biopharmaceuticals/Dynavax/GlaxoSmithKline
Heat Biologics Inc./University of Miami
Inovio Pharmaceuticals Inc
Janssen Pharmaceutical
Sanofi Pasteur/GlaxoSmithKline (GSK)
Moderna/NIAID
Novavax
Sanofi Pasteur/Translate Bio Inc.
Vaxart Inc.
Altimmune
Medicago
BioNTech/Pfizer/Fosun Pharma
GeoVax/BravoVax
Arcturus Therapeutics/Duke-NUS
CanSino Biological Inc/Beijing Institute of Biotechnology
Takis Biotech/Applied DNA Sciences/Evvivax
Cobra Biologics/Karolinska Institute
Zydus Cadila
Codagenix/Serum Institute of India
Greffex
ExpreS2ion Biotechnologies ApS
Vaxil Bio Therapeutics
Flow Pharma Inc
AJ Vaccines
Generex Biotechnology/EpiVax
Immunomic Therapeutics/EpiVax/PharmaJet
iBio Inc/CC-Pharming Ltd/Infectious Disease Research Institute
VIDO-InterVac/University of Saskatchewan/International Vaccine Institute
Tonix Pharmaceuticals/Southern Research
IAVI/Batavia Biosciences
Curevac
Imophoron Ltd/University of Bristol
BioNet Asia
Sinovac/Dynavax
BIOCAD
University of Pittsburgh

Single User License Copy and Other Purchase Options@ https://www.arcognizance.com/purchase/960035 

Table Of Content:

Chapter One: Executive Summary

Chapter Two: Coronavirus (COVID-19) – Introduction, Pathogen Characteristics, Signs and Symptoms, Transmission and Prevention
2.1 Introduction
2.2 Pathogen Characteristics
2.3 Signs and Symptoms
2.4 Transmission
2.5 Prevention

Chapter Three: Funding in the Coronavirus (COVID-19) Vaccine Research

Chapter Four: Vaccines Developed Against MERS-CoV

Chapter Five: Vaccines Developed Against SARS-CoV

Chapter Six: Coronavirus (COVID-19) Vaccine Clinical Trial Insights by Phase, Company and Country

Chapter Seven: Countries, Territories or Areas with Reported Laboratory-Confirmed Coronavirus (COVID-19) Cases and Deaths

Chapter Eight: Major Partnership and Collaboration Deals in the Coronavirus (COVID – 19) Vaccine Market
8.1 Collaboration Deals
8.2 Partnership Deals

Chapter Nine: Key Vaccine Developers Analysis
9.1 University of Oxford
9.1.1 Business Overview
9.1.2 Promising Coronavirus Vaccines in the Clinical Development
9.1.3 Recent Development
9.2 Clover Biopharmaceuticals/Dynavax/GlaxoSmithKline
9.2.1 Business Overview
9.2.2 Promising Coronavirus Vaccines in the Clinical Development
9.2.3 Recent Development
9.3 Heat Biologics Inc./University of Miami
9.3.1 Business Overview
9.3.2 Promising Coronavirus Vaccines in the Clinical Development
9.3.3 Recent Development
9.4 Inovio Pharmaceuticals Inc
9.4.1 Business Overview
9.4.2 Promising Coronavirus Vaccines in the Clinical Development
9.4.3 Recent Development
9.5 Janssen Pharmaceutical
9.5.1 Business Overview
9.5.2 Promising Coronavirus Vaccines in the Clinical Development
9.5.3 Recent Development
9.6 Sanofi Pasteur/GlaxoSmithKline (GSK)
9.6.1 Business Overview
9.6.2 Promising Coronavirus Vaccines in the Clinical Development
9.6.3 Recent Development
9.7 Moderna/NIAID
9.7.1 Business Overview
9.7.2 Promising Coronavirus Vaccines in the Clinical Development
9.7.3 Recent Development
9.8 Novavax
9.8.1 Business Overview
9.8.2 Promising Coronavirus Vaccines in the Clinical Development
9.8.3 Recent Development
9.9 Sanofi Pasteur/Translate Bio Inc.
9.9.1 Business Overview
9.9.2 Promising Coronavirus Vaccines in the Clinical Development
9.9.3 Recent Development
9.10 Vaxart Inc.
9.10.1 Business Overview
9.10.2 Promising Coronavirus Vaccines in the Clinical Development
9.10.3 Recent Development
9.11 Altimmune
9.11.1 Business Overview
9.11.2 Promising Coronavirus Vaccines in the Clinical Development
9.11.3 Recent Development
9.12 Medicago
9.12.1 Business Overview
9.12.2 Promising Coronavirus Vaccines in the Clinical Development
9.12.3 Recent Development
9.13 BioNTech/Pfizer/Fosun Pharma
9.13.1 Business Overview
9.13.2 Promising Coronavirus Vaccines in the Clinical Development
9.13.3 Recent Development
9.14 GeoVax/BravoVax
9.14.1 Business Overview
9.14.2 Promising Coronavirus Vaccines in the Clinical Development
9.14.3 Recent Development
9.15 Arcturus Therapeutics/Duke-NUS
9.15.1 Business Overview
9.15.2 Promising Coronavirus Vaccines in the Clinical Development
9.15.3 Recent Development
9.16 CanSino Biological Inc/Beijing Institute of Biotechnology
9.16.1 Business Overview
9.16.2 Promising Coronavirus Vaccines in the Clinical Development
9.16.3 Recent Development
9.17 Takis Biotech/Applied DNA Sciences/Evvivax
9.17.1 Business Overview
9.17.2 Promising Coronavirus Vaccines in the Clinical Development
9.17.3 Recent Development
9.18 Cobra Biologics/Karolinska Institute
9.18.1 Business Overview
9.18.2 Promising Coronavirus Vaccines in the Clinical Development
9.18.3 Recent Development
9.19 Zydus Cadila
9.19.1 Business Overview
9.19.2 Promising Coronavirus Vaccines in the Clinical Development
9.19.3 Recent Development
9.20 Codagenix/Serum Institute of India
9.20.1 Business Overview
9.20.2 Promising Coronavirus Vaccines in the Clinical Development
9.20.3 Recent Development
9.21 Greffex
9.21.1 Business Overview
9.21.2 Promising Coronavirus Vaccines in the Clinical Development
9.21.3 Recent Development
9.22 ExpreS2ion Biotechnologies ApS
9.22.1 Business Overview
9.22.2 Promising Coronavirus Vaccines in the Clinical Development
9.22.3 Recent Development
9.23 Vaxil Bio Therapeutics
9.23.1 Business Overview
9.23.2 Promising Coronavirus Vaccines in the Clinical Development
9.23.3 Recent Development
9.24 Flow Pharma Inc
9.24.1 Business Overview
9.24.2 Promising Coronavirus Vaccines in the Clinical Development
9.24.3 Recent Development
9.25 AJ Vaccines
9.25.1 Business Overview
9.25.2 Promising Coronavirus Vaccines in the Clinical Development
9.25.3 Recent Development
9.26 Generex Biotechnology/EpiVax
9.26.1 Business Overview
9.26.2 Promising Coronavirus Vaccines in the Clinical Development
9.26.3 Recent Development
9.27 Immunomic Therapeutics/EpiVax/PharmaJet
9.27.1 Business Overview
9.27.2 Promising Coronavirus Vaccines in the Clinical Development
9.27.3 Recent Development
9.28 iBio Inc/CC-Pharming Ltd/Infectious Disease Research Institute
9.28.1 Business Overview
9.28.2 Promising Coronavirus Vaccines in the Clinical Development
9.28.3 Recent Development
9.29 VIDO-InterVac/University of Saskatchewan/International Vaccine Institute
9.29.1 Business Overview
9.29.2 Promising Coronavirus Vaccines in the Clinical Development
9.29.3 Recent Development
9.30 Tonix Pharmaceuticals/Southern Research
9.30.1 Business Overview
9.30.2 Promising Coronavirus Vaccines in the Clinical Development
9.30.3 Recent Development
9.31 IAVI/Batavia Biosciences
9.31.1 Business Overview
9.31.2 Promising Coronavirus Vaccines in the Clinical Development
9.31.3 Recent Development
9.32 Curevac
9.32.1 Business Overview
9.32.2 Promising Coronavirus Vaccines in the Clinical Development
9.32.3 Recent Development
9.33 Imophoron Ltd/University of Bristol
9.33.1 Business Overview
9.33.2 Promising Coronavirus Vaccines in the Clinical Development
9.33.3 Recent Development
9.34 BioNet Asia
9.34.1 Business Overview
9.34.2 Promising Coronavirus Vaccines in the Clinical Development
9.34.3 Recent Development
9.35 Sinovac/Dynavax
9.35.1 Business Overview
9.35.2 Promising Coronavirus Vaccines in the Clinical Development
9.35.3 Recent Development
9.36 BIOCAD
9.36.1 Business Overview
9.36.2 Promising Coronavirus Vaccines in the Clinical Development
9.36.3 Recent Development
9.37 University of Pittsburgh
9.37.1 Business Overview
9.37.2 Promising Coronavirus Vaccines in the Clinical Development
9.37.3 Recent Development

Other Trending Report

Coronavirus (COVID 19) Vaccine, Pipeline Assessment 2020

About Us:
Analytical Research Cognizance (ARC) is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARC’s potential.
ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:
Ranjeet Dengale
Director Sales
Analytical Research Cognizance
+1 (646) 403-4695, +91 90967 44448
Email: sales@arcognizance.com